Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 327, Issue 10, Pages 980-983Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2022.1243
Keywords
-
Categories
Funding
- NIA [K23 AG058806]
- Agency for Healthcare Research and Quality [U19 HS024075]
Ask authors/readers for more resources
This study assesses the allocation of limited monoclonal antibody therapy to the Medicare beneficiaries with the highest risk of severe COVID-19 among a population of fee-for-service patients between November 2020 and August 2021.
This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
